Human Genomics

CORRECTION

Open Access

Correction: Landscape of germline pathogenic variants in patients with dual primary breast and lung cancer

Ning-Yuan Lee[1], Melissa Hum[1], Sabna Zihara[1], Lanying Wang[2], Matthew K. Myint[1], Darren Wan-Teck Lim[2,3], Chee-Keong Toh[2], Anders Skanderup[4], Jens Samol[5,6], Min-Han Tan[7], Peter Ang[8], Soo-Chin Lee[9,10], Eng-Huat Tan[2,11], Gillianne G. Y. Lai[2,3], Daniel S. W. Tan[2,3,4,11], Yoon-Sim Yap[2,3] and Ann S. G. Lee[1,3,12*]

Correction: Human Genomics (2023) 17:66
https://doi.org/10.1186/s40246-023-00510-7

Following publication of the original article [1], the authors reported that some words in Table 1 were out of alignment and it needed to be corrected.

The correct Table 1 has been provided in this correction.

The original article [1] has been corrected.

The original article can be found online at https://doi.org/10.1186/s40246-023-00510-7.

*Correspondence:
Ann S. G. Lee
gmslimsg@nus.edu.sg
[1] Division of Cellular and Molecular Research, National Cancer Centre Singapore, 30 Hospital Boulevard, Singapore 168583, Singapore
[2] Division of Medical Oncology, National Cancer Centre Singapore, 30 Hospital Boulevard, Singapore 168583, Singapore
[3] SingHealth Duke-NUS Oncology Academic Clinical Programme (ONCO ACP), Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore
[4] Genome Institute of Singapore, 60 Biopolis St, Singapore 138672, Singapore
[5] Medical Oncology Department, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore
[6] Johns Hopkins University, Baltimore, MD 21218, USA
[7] Lucence Diagnostics Pte Ltd, 211 Henderson Road, Singapore 159552, Singapore
[8] Oncocare Cancer Centre, Gleneagles Medical Centre, 6 Napier Road, Singapore 258499, Singapore
[9] Department of Hematology-Oncology, National University Cancer Institute, Singapore (NCIS), National University Health System, 5 Lower Kent Ridge Road, Singapore 119074, Singapore
[10] Cancer Science Institute, Singapore (CSI), National University of Singapore, 14 Medical Dr, Singapore 117599, Singapore
[11] Clinical Trials and Epidemiological Sciences, National Cancer Centre Singapore, 30 Hospital Boulevard, Singapore 168583, Singapore
[12] Department of Physiology, Yong Loo Lin School of Medicine, Medical Drive, National University of Singapore, Singapore 117593, Singapore

Table 1 Demographic and clinicopathological characteristics of patient cohort

Characteristics (n = 55)			**n (%)**
Ethnicity			
Chinese			50 (90.9)
Others			5 (9.1)
Smoking status			
Never-smoker			52 (94.5)
Smoker			3 (5.5)
Temporal occurrence of lung and breast cancer diagnosis			
Lung cancer occurred first			5 (9.1)
Breast cancer occurred first			38 (69.1)
Synchronous (within 6 months)			12 (21.8)
Family cancer history (any primary)			
First degree			27 (49.1)
Second degree			4 (7.3)
No known history			24 (43.6)
Family history of breast and/or lung cancer			
First degree			8 (14.5)
Second degree			2 (3.6)
Breast cancer		**Lung cancer**	
Diagnosis year	1976–2018	Diagnosis year	2005–2018
Median age, years (range)	55 (34–81)	Median age, years (range)	65 (48–78)
Histology	**n (%)**	**Histology**	**n (%)**
Ductal carcinoma in situ (DCIS)	5 (9.1)	Adenocarcinoma (ADC)	44 (80)
Infiltrating ductal carcinoma (IDC)	33 (60)	Neuroendocrine carcinoma	
Infiltrating lobular carcinoma (ILC)	4 (7.3)	Carcinoid	2 (3.6)
DCIS + DCIS (bilateral)	1 (1.8)	SCLC	3 (5.5)
IDC + DCIS (bilateral)	2 (3.6)	Undifferentiated	1 (1.8)
IDC + ILC (bilateral)	2 (3.6)	Lymphoepithelioma-like carcinoma (LELC)	1 (1.8)
IDC + unknown subtype (bilateral)	1 (1.8)	ADC + carcinoid (bilateral, synchronous)	1 (1.8)
Mucinous adenocarcinoma	3 (5.5)	ADC + ADC (bilateral, synchronous)	1 (1.8)
Subtype not specified (NOS)	4 (7.3)	ADC + ADC (same side, synchronous)	2 (3.6)
Staging[a]		**Staging**[b]	
0	6 (10.9)	0	0 (0.0)
I/II	44 (80.0)	I/II	26 (47.3)
III	4 (7.3)	III	7 (12.7)
IV	1 (1.8)	IV	22 (40.0)
Hormone and HER2 status[c]		**EGFR status** (adenocarcinoma only, n = 49)	
ER		Not tested	4 (8.2)
Positive	36 (65.4)	Tested	45 (91.8)
Negative	10 (18.2)	**Mutant**	33 (73.3*)
Not tested/unknown	9 (16.4)	Exon19 del	19 (57.6^)
PR		L858R	11 (33.3^)
Positive	30 (54.5)	Others	3 (9.1^)
Negative	15 (27.3)	**Wild type**	12 (26.7*)
Not tested/unknown	10 (18.2)		
HER2			
Positive	4 (7.3)		
Negative	28 (50.9)		
Not tested/unknown/equivocal	23 (41.8)		

Table 1 (continued)

[a] For bilateral cancers, higher stage was taken

[b] All 4 multi-lesion cases are stage I

[c] For bilateral cancers, higher stage's status was presented

*Over tested cases (total n = 45)

^ Over mutant cases (total n = 33)

Published online: 14 August 2023

Reference

1. Lee NY, Hum M, Zihara S, et al. Landscape of germline pathogenic variants in patients with dual primary breast and lung cancer. Hum Genomics. 2023;17:66. https://doi.org/10.1186/s40246-023-00510-7.

Publisher's Note